Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT02592564
Other study ID # UMESTUDIEN-II
Secondary ID
Status Active, not recruiting
Phase N/A
First received October 23, 2015
Last updated August 31, 2017
Start date October 2015
Est. completion date May 2021

Study information

Verified date August 2017
Source Linkoeping University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluates underlying psychological and biological mediators in Internet-delivered cognitive behavior therapy for adults with social anxiety disorder.


Description:

Internet-delivered cognitive behavior therapy for social anxiety disorder has previously demonstrated to target and affect the brain´s fear network, typically neural response in the amygdala ameliorate after effective psychological treatment. Commonly, neuroimaging studies have performed brain imaging at pre- and post-intervention, yet, longitudinal study designs including several repeated measures of neural response over the course of treatment are currently missing in anxiety disorder. In the current study the participants will undergo magnetic resonance imaging (MRI) at four occasion. a) Twice before treatment initiation (9 weeks apart), b) at week 4 (during treatment), c) and directly after treatment termination.

Biological aging can be quantified at the individual cell level by measuring telomere length in peripheral immune cells (leukocytes). Telomeres are located at the end of each chromosome and protect the genetic material during cell division. Telomerase is an enzyme that can lengthen telomeres, and have in this way a protective function against accelerated cellular aging. Variations in these bodily processes have been associated with psychiatric manifestations such as anxiety and depression. In the current study the participant´s telomere length and telomerase activity will be assessed at three occasion. a) Twice before treatment initiation (9 weeks apart), and b) directly after treatment termination.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 50
Est. completion date May 2021
Est. primary completion date April 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Social Anxiety Disorder as primary diagnosis (DSM-5)

- Otherwise somatically healthy

- Willingness to participate in a symptom provocation brain imaging trial

Exclusion Criteria:

- Concurrent psychological treatment

- Treatment of social anxiety within the three months preceding the study

- Chronic use of prescribed medication that could influence the results (anxiolytic or antidepressant drugs, certain hypnotics or herbs like St Johns Wort)

- Contraindications for MRI investigation (implants or other metal objects in the body, brain and heart operations)

- Pregnancy or planned pregnancy during the first 6 months of the study period

- Postmenopausal women

- Any neurological disorders

- Depressive symptoms, as determined by scoring more than 20 on the MADRS questionnaire (self-report version)

- Suicidal ideation (scoring more than 2) on the self-report version of MADRS, item 9

- Suicide at moderate risk (MINI v7)

- Bipolar disorder (MINI v7)

- Psychotic syndromes (MINI v7)

- Substance abuse disorders (MINI v7)

- Alcohol abuse (MINI v7)

- Any eating disorder (MINI v7)

- Antisocial personality disorder (MINI v7)

Study Design


Intervention

Behavioral:
Internet-delivered cognitive behavior therapy
Internet-delivered cognitive behavior therapy for social anxiety disorder. Similar to previous studies in our research group, the treatment will be delivered during 9 weeks. Each week the participant will be introduced to a module containing text material and homework assignments. The participants will receive feedback via text by a clinical psychologist once a week.

Locations

Country Name City State
Sweden Umeå university Umeå

Sponsors (5)

Lead Sponsor Collaborator
Linkoeping University Karolinska Institutet, Stockholm University, Umeå University, Uppsala University

Country where clinical trial is conducted

Sweden, 

References & Publications (4)

Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissiota A, Långström B, Fredrikson M. Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitive-behavioral therapy. Arch Gen Psychiatry. 2002 May;59(5):425-33. — View Citation

Lindqvist D, Epel ES, Mellon SH, Penninx BW, Révész D, Verhoeven JE, Reus VI, Lin J, Mahan L, Hough CM, Rosser R, Bersani FS, Blackburn EH, Wolkowitz OM. Psychiatric disorders and leukocyte telomere length: Underlying mechanisms linking mental illness with cellular aging. Neurosci Biobehav Rev. 2015 Aug;55:333-64. doi: 10.1016/j.neubiorev.2015.05.007. Epub 2015 May 18. Review. — View Citation

Månsson KN, Carlbring P, Frick A, Engman J, Olsson CJ, Bodlund O, Furmark T, Andersson G. Altered neural correlates of affective processing after internet-delivered cognitive behavior therapy for social anxiety disorder. Psychiatry Res. 2013 Dec 30;214(3):229-37. doi: 10.1016/j.pscychresns.2013.08.012. Epub 2013 Sep 21. — View Citation

Månsson KN, Frick A, Boraxbekk CJ, Marquand AF, Williams SC, Carlbring P, Andersson G, Furmark T. Predicting long-term outcome of Internet-delivered cognitive behavior therapy for social anxiety disorder using fMRI and support vector machine learning. Transl Psychiatry. 2015 Mar 17;5:e530. doi: 10.1038/tp.2015.22. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Resting-state fMRI 6 minutes Salami et al., 2014, PNAS Baseline 1 (week 0), Baseline 2 (week 9), week 13 during treatment, week 20 (post-treatment)
Other Self-referential criticism Blair et al., 2008, Arch Gen Psych Baseline 1 (week 0), Baseline 2 (week 9), week 13 during treatment, week 20 (post-treatment)
Other Hariri´s Hammer (emotional face perception) Hariri et al., 2002, Science Baseline 1 (week 0), Baseline 2 (week 9), week 13 during treatment, week 20 (post-treatment)
Other Brain habituation during face perception Fischer et al., 2003, Brain Research Bulletin Baseline 1 (week 0), Baseline 2 (week 9), week 13 during treatment, week 20 (post-treatment)
Other Diffusion Tensor Imaging (DTI) Salami et al., 2012, Biochim Biophys Acta Baseline 1 (week 0), Baseline 2 (week 9), week 13 during treatment, week 20 (post-treatment)
Other Leukocyte telomere length Lindqvist et al., 2015, Neurosci Biobehav Rev Baseline 1 (week 0), Baseline 2 (week 9), week 20 (post-treatment)
Other Telomere terminal transferase (telomerase) Wolkowitz et al., 2012, Mol Psychiatry Baseline 1 (week 0), Baseline 2 (week 9), week 20 (post-treatment)
Primary Clinically Global Impression-Improvement scale (CGI-I; Change from baseline) Clinician administrated telephone-interview to determine the participant´s treatment response rates (very much worse to very much improved) At week 20 (post-treatment), and at 6, 12, and 60 months
Primary Liebowitz Social Anxiety Scale, Self-report version (LSAS-SR; Change from baseline) Self reported social anxiety symptoms on fear (scoring 0-3) and avoidance (scoring 0-3) in 24 social situations. Screening, Baseline 1 (week 0), Baseline 2 (week 9), weekly during treatment (week 10-19), week 20 (post-treatment), and at 6, 12, and 60 months
Secondary Clinically Global Impression-Severity scale (CGI-S) Clinician administrated telephone-interview to determine the participant´s severity of illness Screening, week 20 (post-treatment), and at 6, 12, and 60 months
Secondary Social Phobia Screening Questionnaire (SPSQ) Self reported social anxiety symptoms on distress (scoring 0-4) in 24 social situations. Screening, week 20 (post-treatment), and at 6, 12, and 60 months
Secondary Beck Anxiety Inventory (BAI) Self reported anxiety symptoms Screening, week 20 (post-treatment), and at 6, 12, and 60 months
Secondary Social Interaction Anxiety Scale (SIAS) Self reported social anxiety symptoms on distress (scoring 0-4) in 21 social situations. Screening, week 20 (post-treatment), and at 6, 12, and 60 months
Secondary Social Phobia Scale (SPS) Self reported social anxiety symptoms on distress (scoring 0-4) in 20 social situations. Screening, week 20 (post-treatment), and at 6, 12, and 60 months
Secondary Montgomery Åsberg Depression Rating Scale, Self-report version (MADRS-S) Self reported depressive symptoms (scoring 0-6). Screening, Baseline 1 (week 0), Baseline 2 (week 9), week 13 during treatment, week 20 (post-treatment), and at 6, 12, and 60 months
Secondary Subjective unit of discomfort on fear and distress (SUD) Self reported scoring 0-100 on fear and distress separately Before experimental tasks while undergoing MRI, at Baseline 1 (week 0), Baseline 2 (week 9), week 13 during treatment, week 20 (post-treatment)
Secondary Social Probability/Cost Questionnaire 40 items scoring 0 to 8. Foa et al., 1996, J Abnormal Psychology Baseline 1 (week 0), Baseline 2 (week 9), week 13 during treatment, week 20 (post-treatment), and at 6, 12, and 60 months
Secondary Quality of Life (QOLI) Screening, week 20 (post-treatment), and at 6, 12, and 60 months
Secondary Social Network Index (SNI) Bickart et al., 2010, Nat Neurosci Baseline 1 (week 0)
Secondary Brown Attention-Deficit Disorder Scales (Brown ADD) Baseline 1 (week 0)
Secondary Difficulties in Emotion Regulation Scale (DERS) Baseline 1 (week 0), Baseline 2 (week 9), week 13 during treatment, week 20 (post-treatment), and at 6, 12, and 60 months
Secondary Treatment Credibility Scale (TCS) Baseline 2 (week 9), week 13 during treatment
Secondary Revised NEO Personality Inventory (NEO-PI-R) Baseline 1 (week 0)
Secondary Insomnia Severity Index (ISI) Baseline 1 (week 0)
Secondary Karolinska Sleep Questionnaire (KSQ) Baseline 1 (week 0)
Secondary State-Trait Anxiety Inventory (STAI-T) Baseline 1 (week 0)
Secondary State-Trait Anxiety Inventory (STAI-S) Baseline 1 (week 0), Baseline 2 (week 9), week 13 during treatment, week 20 (post-treatment)
Secondary MINI International Neuropsychiatric Interview Swedish version 7.0.0 Screening
See also
  Status Clinical Trial Phase
Completed NCT03535805 - Transdiagnostic, Cognitive and Behavioral Intervention for in School-aged Children With Emotional and Behavioral Disturbances N/A
Active, not recruiting NCT05006976 - A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study N/A
Recruiting NCT05419934 - EMDR Therapy in Young Children, a Double-blinded Randomized Controlled Trial N/A
Active, not recruiting NCT04136054 - Better Sleep in Psychiatric Care - Anxiety and Affective Disorders N/A
Completed NCT04091139 - Research of Unified Protocol for the Treatment of Common Mental Disorders in Adolescents in Hong Kong Phase 2/Phase 3
Completed NCT04647318 - Physiological Response to Self-compassion Versus Relaxation N/A
Active, not recruiting NCT05114824 - Acceptability and Feasibility of an 8-week Online Mindfulness-Based Cognitive Therapy Program Among Undergraduate Students N/A
Recruiting NCT05843695 - Enhancing Psychotherapy for Veterans and Service Members With PTSD and Anxiety N/A
Completed NCT05078450 - Mood Lifters Online for Graduate Students and Young Professionals N/A
Not yet recruiting NCT06162624 - Pilot Effectiveness Trial of an ACT Self-help Workbook Tailored Specifically for Prisons N/A
Not yet recruiting NCT05747131 - Emotion Detectives In-Out: Feasibility and Efficacy of a Blended Version of the Unified Protocol for Children N/A
Not yet recruiting NCT05863637 - Intensive Short-Term Dynamic Psychotherapy (ISTDP) for Anxiety Diagnoses in a Primary Care Setting N/A
Not yet recruiting NCT05225701 - Efficacy of a Transdiagnostic Guided Internet-Delivered Intervention for Emotional, Trauma and Stress-Related Disorders. N/A
Completed NCT02579915 - Developing a Low-Intensity Primary Care Intervention for Anxiety Disorders (AIM-PC) N/A
Recruiting NCT02376959 - Effect of Spiritist "Passe" Energy Therapy in Reducing Anxiety in Volunteers N/A
Recruiting NCT02186366 - Efficacy Study of Abdominal Massage Therapy to Treat Generalized Anxiety Disorder of Deficiency of Both Heart and Spleen Type N/A
Not yet recruiting NCT02126787 - Short-term, Intensive Psychodynamic Group Therapy Versus Cognitive-behavioral Group Therapy in the Day Treatment N/A
Withdrawn NCT01953042 - Benefits of a Psychoeducation Program for Those Awaiting Treatment for OCD and OCD Spectrum Disorders N/A
Completed NCT02134730 - School-based Universal Prevention for Anxiety and Depression in Sweden: A Cluster-randomized Trial N/A
Completed NCT01636791 - CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care Phase 3

External Links